A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension

NCT03504917 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

322

Enrollment

INDUSTRY

Sponsor class

Stopped A futility analysis assessed that the study is highly unlikely to meet the pre-defined primary objective of the study. No new safety concerns were identified.

Conditions

Autism Spectrum Disorder

Interventions

DRUG: Balovaptan
DRUG: Placebo

Sponsor

Hoffmann-La Roche